| scholarly article | Q13442814 |
| P2093 | author name string | Bryan D Smith | |
| Daniel L Flynn | |||
| Ningyi Tiao | |||
| Verlene Henry | |||
| John F de Groot | |||
| Soon Young Park | |||
| Yuji Piao | |||
| P2860 | cites work | Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. | Q55475281 |
| Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations | Q56688160 | ||
| Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma | Q73819317 | ||
| VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex | Q24293027 | ||
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 | Q27701843 | ||
| A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo | Q28183526 | ||
| Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene | Q28202069 | ||
| Invasive growth: a MET-driven genetic programme for cancer and stem cells | Q28253680 | ||
| Stromal fibroblasts in cancer initiation and progression | Q29618873 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition | Q30414265 | ||
| Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence | Q31148416 | ||
| Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes | Q33688579 | ||
| Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth | Q33732486 | ||
| Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape | Q34783533 | ||
| Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma | Q35673676 | ||
| Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo | Q35746501 | ||
| Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors | Q35967197 | ||
| Met and hepatocyte growth factor/scatter factor expression in human gliomas | Q36894692 | ||
| High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor | Q37507256 | ||
| Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. | Q38198121 | ||
| Glioma in 2014: unravelling tumour heterogeneity-implications for therapy | Q38308027 | ||
| Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition | Q39134430 | ||
| Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype | Q39281709 | ||
| Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation | Q40408804 | ||
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 | ||
| Transcriptional mimicry by tumor-associated stroma | Q41152059 | ||
| Tumor measurement in the nude mouse | Q41355093 | ||
| Prospective, high-throughput molecular profiling of human gliomas | Q41970534 | ||
| The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme | Q43819146 | ||
| Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation | Q44065642 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| MET gain in diffuse astrocytomas is associated with poorer outcome | Q45839064 | ||
| Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. | Q45866300 | ||
| Prognostic significance of c-Met expression in glioblastomas | Q46170165 | ||
| MET Signaling Regulates Glioblastoma Stem Cells | Q48498498 | ||
| Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. | Q50754378 | ||
| Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. | Q55072288 | ||
| The MET oncogene is a functional marker of a glioblastoma stem cell subtype. | Q55462084 | ||
| P433 | issue | 9 | |
| P921 | main subject | glioblastoma | Q282142 |
| bevacizumab | Q413299 | ||
| neoplastic invasiveness | Q112498967 | ||
| P304 | page(s) | 1230-1241 | |
| P577 | publication date | 2016-03-09 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models | |
| P478 | volume | 18 |
| Q39259089 | Angiogenesis inhibitors in tackling recurrent glioblastoma |
| Q57116617 | Characterization and potential roles of bone marrow-derived stromal cells in cancer development and metastasis |
| Q54977810 | Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma. |
| Q90466611 | Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma |
| Q42778255 | Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion. |
| Q57111067 | Glioblastoma Treatments: An Account of Recent Industrial Developments |
| Q92322464 | Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI |
| Q92787423 | Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1 |
| Q92912403 | MET in glioma: signaling pathways and targeted therapies |
| Q33853991 | Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy |
| Q96302541 | MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT |
| Q92052235 | Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer |
| Q28067777 | Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer |
| Q48369496 | Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. |
| Q93156088 | Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma |
| Q92511358 | Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors |
| Q39034031 | The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia |
| Q51822856 | The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors |
| Q37567174 | The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma |
| Q39166795 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I. |
Search more.